Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients.

Article Details

Citation

Wu S, Xing Q, Gao R, Li X, Gu N, Feng G, He L

Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients.

Neurosci Lett. 2005 Mar 7;376(1):1-4. Epub 2004 Dec 2.

PubMed ID
15694263 [ View in PubMed
]
Abstract

Previous studies have demonstrated that the -141C Ins/Del and TaqI A polymorphisms in the DRD2 gene affect the density of the dopamine D2 receptor. The present study examines the correlation between these two polymorphisms and the therapeutic response to chlorpromazine, a typical antipsychotic drug, in 135 inpatients with schizophrenia. Clinical symptoms were evaluated using the Brief Psychiatry Rating Scale (BPRS) before and after 8 weeks of treatment with 300-600 mg/day of chlorpromazine. Our results show that genotyping -141C Ins/Del may help to predict the efficacy of chlorpromazine treatment (P=0.01) due to the fact that patients with no Del allele showed greater improvement than those with Del allele on the overall BPRS (P=0.03), and that, therefore, the potential for therapy in patients with schizophrenia is related to the -141C Ins/Del polymorphism in the DRD2 gene. However, no such relationship was found for the TaqI A polymorphism.

DrugBank Data that Cites this Article

Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
AcepromazineDopamine D2 receptorProteinHumans
Yes
Antagonist
Details
ChlorpromazineDopamine D2 receptorProteinHumans
Yes
Antagonist
Details
PipotiazineDopamine D2 receptorProteinHumans
Yes
Antagonist
Details
ThioproperazineDopamine D2 receptorProteinHumans
Yes
Antagonist
Details
ThiothixeneDopamine D2 receptorProteinHumans
Yes
Antagonist
Details